恶性胸膜间皮瘤修订版RECIST 1.1疗效评估标准
该指南针对恶性胸膜间皮瘤肿瘤测量与疗效评估的独特困难,更新了2004年发布的修改版RECIST标准。新版整合RECIST 1.1推荐并解决既往未明确的实际问题,包括可测量病灶定义、测量位置、非胸膜病变、病理淋巴结评估及双侧胸膜病变等,建议在下一代临床试验中采用以统一评估。
要点
- 推荐采用修改版RECIST 1.1作为间皮瘤疗效评估标准。
- 新标准明确可测量病灶定义、测量位置及双侧胸膜病变处理。
- 新标准补充非胸膜病变、病理淋巴结及疾病进展的评估规则。
核心结论
- 建议采用修改版RECIST 1.1标准统一恶性胸膜间皮瘤的肿瘤测量与疗效评估。
研究设计与样本
- 基于2004年修改版RECIST研究论文的更新指南,整合RECIST 1.1推荐及后续临床研究证据。
主要发现
- 修改版RECIST实际应用因解读差异导致间皮瘤临床试验疗效评估不准确和不一致。
- 新指南解决了既往被忽视或描述不足的肿瘤测量问题,并澄清了模糊或困难的测量议题。
关键数值与推荐
- 新指南涵盖最小可测量疾病定义、可测量病灶定义、可接受测量位置、非胸膜病变考量、非可测量胸膜病变特征、病理淋巴结评估、疾病进展确立及双侧胸膜病变适应。
临床怎么用
- 在间皮瘤临床试验中采用修改版RECIST 1.1进行肿瘤测量和疗效评估以提高一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. METHODS: The current de facto standard for the assessment of mesothelioma tumor response, "modified RECIST" (Response Evaluation Criteria in Solid Tumors), was published in 2004 as a research paper. Practical application of the modified RECIST guidelines has suffered from varied interpretations, resulting in inaccuracies and inconsistencies in tumor response assessment across and within mesothelioma clinical trials. The presented "modified RECIST 1.1 for mesothelioma" response assessment guidelines provide a much-needed update that incorporates recommendations from RECIST 1.1 and approaches to other practical issues, including: (1) definition of minimally measurable disease; (2) definition of measurable lesions; (3) acceptable measurement location; (4) non-pleural disease considerations; (5) characterization of non-measurable pleural disease; (6) assessment of pathological lymph nodes; (7) establishing progressive disease; and (8) accommodations for bilateral pleural disease. RESULTS: These modified RECIST 1.1 guidelines for mesothelioma tumor response collate and apply research published since the development of modified RECIST, align modified RECIST with RECIST 1.1, address those aspects of tumor measurement that were neglected or not well characterized in the modified RECIST paper, and clarify ambiguous or difficult measurement issues that have been highlighted through the subsequent decade of clinical trials research. CONCLUSION: Adoption of the modified RECIST 1.1 guidelines for mesothelioma is recommended to harmonize the application of tumor measurement and response assessment across the next generation of clinical trials in this disease.
引用
- Armato SG, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). J Thorac Oncol. 2018. PMID: 29753121. doi:10.1016/j.jtho.2018.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。